Medicenna Therapeutics (TSE:MDNA) Trading Up 14.3% – Here’s Why

Medicenna Therapeutics Corp. (TSE:MDNA)’s stock price was up 14.3% during trading on Monday . The stock traded as high as C$0.72 and last traded at C$0.72. Approximately 127,392 shares changed hands during trading, an increase of 20% from the average daily volume of 105,837 shares. The stock had previously closed at C$0.63.

Medicenna Therapeutics Trading Up 6.5%

The firm’s 50-day moving average is C$0.67 and its 200 day moving average is C$0.97. The company has a current ratio of 2.68, a quick ratio of 4.65 and a debt-to-equity ratio of 3.30. The firm has a market capitalization of C$55.06 million, a price-to-earnings ratio of -4.40 and a beta of 2.90.

Medicenna Therapeutics (TSE:MDNA) last posted its earnings results on Thursday, April 30th. The company reported C($0.06) EPS for the quarter. Medicenna Therapeutics had a negative return on equity of 103.51% and a negative net margin of 533,640.00%. On average, equities analysts predict that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current fiscal year.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.